PT - JOURNAL ARTICLE AU - Camp, Chris C. AU - Noble, Stephanie AU - Scheinost, Dustin AU - Stringaris, Argyris AU - Nielson, Dylan M. TI - Test-retest reliability of functional connectivity in depressed adolescents AID - 10.1101/2022.10.11.22280962 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.11.22280962 4099 - http://medrxiv.org/content/early/2022/10/13/2022.10.11.22280962.short 4100 - http://medrxiv.org/content/early/2022/10/13/2022.10.11.22280962.full AB - The test-retest reliability of fMRI functional connectivity is a key factor in the identification of reproducible biomarkers for psychiatric illness. Low reliability limits the observable effect size of brain-behavior associations. Despite this important connection to clinical applications of fMRI, few studies have explored reliability in populations with psychiatric illnesses or across age groups. We investigate the test-retest reliability of functional connectivity in a longitudinal cohort of adolescents with and without major depressive disorder (MDD). Measuring reliability is complex and several metrics exist that can offer unique perspectives: for example, univariate metrics capture reliability of a single connection at a time while multivariate metrics reflect stability of the entire connectome. We compare a widely used univariate metric, intraclass correlation coefficient (ICC), and two multivariate metrics, fingerprinting and discriminability. Depressed adolescents were more reliable than healthy adolescents at the univariate level (0.34 > 0.24; Wilcoxon rank-sum: p < .001), and both groups had poor average ICCs (<0.4). Multivariate reliability was high in both groups: fingerprinting (FIHV = 0.53; FIMDD = 0.45; Poisson(1) test p < .001) and discriminability were above chance (DiscrHV = 0.75; DiscrMDD = 0.76; 500-fold permutation test p < .01). Reliability was not associated with symptoms or medication, suggesting that there is not a strong relationship between depression and reliability. These findings support the shift towards multivariate analysis for improved power and reliability.Competing Interest StatementDr. Stringaris is a coauthor of the Affective Reactivity Index (ARI), a cost-free psychometric instrument. He has received royalties from Cambridge University Press for The Maudsley Reader in Phenomenological Psychiatry and Oxford University Press for Disruptive Mood: Irritability in Children and Adolescents.Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03388606?cond=Major+Depressive+Disorder&cntry=US&state=US%3AMD&city=Bethesda&draw=3&rank=46 Funding StatementThis research was supported by the Intramural Research Program of NIMH/National Institutes of Health (NIH; ZIA-MH002957-01 to A.S.). This work used computational resources from the National Institutes of Health High-Performance Computing Biowulf Cluster Biowulf cluster (http://hpc.nih.gov) and the Yale Center for Research Computing Farnam cluster (https://docs.ycrc.yale.edu/).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Institute of Mental Health Institutional Review Board (clinical trial no. NCT03388606) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code referenced in the present study will be made available after an embargo period.